A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-06)

• Biological: PF-05280014
  
  Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
  Other Name: Trastuzumab-Pfizer
• Biological: Herceptin®
  
  Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
  Other Name: Trastuzumab-US

• Experimental: PF-05280014
  
  Intervention: Biological: PF-05280014
• Active Comparator: Trastuzumab-US
  
  Intervention: Biological: Herceptin®

Inclusion Criteria:

• Body Mass Index (BMI) of 17.5 to 30.5 kg^m2; and a total body weight >50 kg (110 lbs).
• Left ventricular ejection fraction (LVEF) within the normal range as measured by echocardiogram (ECHO) within 8 weeks prior to randomization.
• Subjects who have previously been exposed to a biologic agent (other than a HER2 inhibitor) may enroll provided that at least 3 months have passed since the last administration of that drug.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• Previous exposure to an anti-HER2 antibody.
• History of serious allergic or anaphylactic reaction to a therapeutic drug or benzyl alcohol.